Vaccination against Haemonchus contortus: performance of native parasite gut membrane glycoproteins in Merino lambs grazing contaminated pasture.
In a replicated trial, parasitological and antibody responses of grazing weaner Merino sheep were assessed following vaccination with gut membrane proteins prepared from adult worms of the gastrointestinal nematode, Haemonchus contortus. Each vaccinated animal received 100 microg native H11 and 100 microg native H-gal-GP combined together in 5mg Quil A administered intramuscularly on days 0, 34, 80 and 127. Control animals received 5mg Quil A alone on the same days. Vaccinated and unvaccinated control animals grazed pastures contaminated with the parasite from day 34 of the trial, and levels of parasitism were monitored by worm-egg counts (WECs) in faeces and packed cell volumes (PCVs) in blood. The level of larval contamination on pasture was estimated from the worm counts of tracer sheep introduced monthly to the paddocks. WECs and anaemia were significantly reduced in vaccinated animals, and, in contrast to vaccinates, all control sheep required salvage treatment with anthelmintic. By the last 2 months of the trial, pastures grazed by vaccinated animals had significantly lower contamination with H. contortus larvae. Vaccinated animals had high levels of vaccine antigen-specific IgG1 and IgG2 antibodies in plasma, whereas those responses in the control sheep were very low. IgG1 titres in the vaccinated group, but not IgG2 titres, were inversely correlated with worm-egg counts. The levels of systemic IgA and IgE remained low but increased in both groups towards the end of the experiment most probably from exposure to the natural infection from pasture. The results showed that H11 and H-gal-GP behaved like "hidden" antigens producing high levels of protection that were probably mediated through mechanisms involving antibodies, and in particular, IgG1. It was concluded that if similar protective effects could be obtained with recombinant versions of the proteins present in either H11 or H-gal-GP, then the prospects for a commercial Haemonchus vaccine were real.
LeJambre
L F
LF
CSIRO Livestock Industries, F.D. McMaster Laboratory, Private Mail Bag, Armidale, NSW 2350, Australia.leo.lejambre@CSIRO.au
Windon
R G
RG
Smith
W D
WD
D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D006188:Haemonchiasis / Q000517:prevention & control / Q000662:veterinary*; D006189:Haemonchus / Q000276:immunology*; D015801:Helminth Proteins / Q000276:immunology*; D008297:Male; D010270:Parasite Egg Count / Q000662:veterinary; D011897:Random Allocation; D012756:Sheep; D012757:Sheep Diseases / Q000517:prevention & control*; D013997:Time Factors; D014611:Vaccination / Q000379:methods / Q000662:veterinary*
D000909:Antibodies, Helminth; D015801:Helminth Proteins